Tempus AI, Inc. $TEM Shares Acquired by Washington Trust Advisors Inc.

Key Points

• Washington Trust Advisors increased its Tempus AI stake by 49.1% in the second quarter, bringing its holdings to 89,166 shares valued at approximately $5.17 million. Several other institutional investors also initiated or expanded positions, with institutions and hedge funds owning 24.22% of the stock.
• Tempus AI reported quarterly revenue of $382.49 million, up 21.6% year over year, and an adjusted loss of $0.04 per share, beating analysts’ expected loss of $0.14. Despite improved results, the company remains unprofitable, with a negative net margin of 17.77%.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and a $68.93 price target, while insiders have sold more than 1 million shares worth approximately $57 million over the past 90 days.

Washington Trust Advisors Inc. increased its stake in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 49.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 89,166 shares of the company's stock after buying an additional 29,347 shares during the quarter. Washington Trust Advisors Inc.'s holdings in Tempus AI were worth $5,165,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Ameritas Advisory Services LLC acquired a new position in shares of Tempus AI during the second quarter valued at $678,000. Straight Path Wealth Management acquired a new stake in shares of Tempus AI in the 2nd quarter worth about $229,000. Turner Financial Group Inc. acquired a new stake in shares of Tempus AI in the 2nd quarter worth about $582,000. Odyssean LLC bought a new stake in Tempus AI in the 2nd quarter valued at about $897,000. Finally, Nykredit A S bought a new stake in Tempus AI in the 2nd quarter valued at about $186,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Tempus AI Stock Performance

Shares of TEM opened at $64.62 on Monday. The firm has a market capitalization of $11.66 billion, a PE ratio of -44.87 and a beta of 3.72. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. The firm has a 50-day moving average price of $55.77 and a 200 day moving average price of $52.13. Tempus AI, Inc. has a 52-week low of $40.77 and a 52-week high of $104.32.

Tempus AI (NASDAQ:TEM - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. During the same period in the previous year, the firm earned ($0.22) EPS. Tempus AI's revenue was up 21.6% on a year-over-year basis. On average, sell-side analysts anticipate that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Tempus AI news, CFO James Rogers sold 26,313 shares of the business's stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $60.00, for a total value of $1,578,780.00. Following the sale, the chief financial officer directly owned 106,024 shares in the company, valued at approximately $6,361,440. The trade was a 19.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Eric P. Lefkofsky sold 238,152 shares of the company's stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $68.39, for a total transaction of $16,287,215.28. Following the completion of the sale, the chief executive officer directly owned 161,848 shares of the company's stock, valued at $11,068,784.72. The trade was a 59.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 1,043,988 shares of company stock valued at $56,963,417. 24.26% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have commented on the stock. Freedom Capital upgraded shares of Tempus AI to a "hold" rating in a research report on Tuesday, June 30th. Raymond James Financial set a $80.00 price target on Tempus AI in a report on Wednesday. Wall Street Zen upgraded Tempus AI from a "sell" rating to a "hold" rating in a research report on Saturday, July 25th. Weiss Ratings lowered Tempus AI from a "sell (d-)" rating to a "sell (e+)" rating in a report on Thursday, August 27th. Finally, TD Cowen restated a "buy" rating on shares of Tempus AI in a research report on Wednesday, July 15th. Eleven equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, Tempus AI has a consensus rating of "Moderate Buy" and a consensus price target of $68.93.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source